BACKGROUND: Only a few cases of essential thrombocythemia in pregnant women have been reported, and the management of this myeloproliferative disorder during pregnancy remains uncertain. We report a successful pregnancy in a patient who had essential thrombocythemia and who was treated with interferon-alpha, and we review the literature for the outcome of similar patients. CASE: A 32-year-old woman, gravida 4, para 3, aborta 0, presented at 18 weeks' gestation with two episodes of amaurosis fugax and an elevated platelet count of 2300 x 10(9)/L. The initiation of interferon-alpha led to a progressive fall of the platelet level, with no occurrence of thrombotic or hemorrhagic manifestations. Serial ultrasound examinations revealed normal fetal and placental development. The patient was delivered of a male infant at 37 weeks. Both child and placenta were normal on examination. CONCLUSION: Our case and the current available data suggest that interferon-alpha may be the best therapeutic option for pregnant patients with essential thrombocythemia in whom myelosuppression is required.
BACKGROUND: Only a few cases of essential thrombocythemia in pregnant women have been reported, and the management of this myeloproliferative disorder during pregnancy remains uncertain. We report a successful pregnancy in a patient who had essential thrombocythemia and who was treated with interferon-alpha, and we review the literature for the outcome of similar patients. CASE: A 32-year-old woman, gravida 4, para 3, aborta 0, presented at 18 weeks' gestation with two episodes of amaurosis fugax and an elevated platelet count of 2300 x 10(9)/L. The initiation of interferon-alpha led to a progressive fall of the platelet level, with no occurrence of thrombotic or hemorrhagic manifestations. Serial ultrasound examinations revealed normal fetal and placental development. The patient was delivered of a male infant at 37 weeks. Both child and placenta were normal on examination. CONCLUSION: Our case and the current available data suggest that interferon-alpha may be the best therapeutic option for pregnant patients with essential thrombocythemia in whom myelosuppression is required.
Authors: Spyridon Arampatzis; Ioannis Stefanidis; Vassilios Lakiopoulos; Luigi Raio; Daniel Surbek; Markus G Mohaupt Journal: Thromb J Date: 2010-06-17
Authors: Mohammad Abu-Tineh; Nancy Kassem; Mohammad Abdul-Jaber Abdulla; Omar Mohammad Ismail; Rola Ghasoub; Mahmood B Aldapt; Mohamed A Yassin Journal: Case Rep Oncol Date: 2020-03-26
Authors: Chul Won Choi; Soo-Mee Bang; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Soo-Jeong Kim; Yeo-Kyeoung Kim; Jinny Park; Jong-Ho Won Journal: Korean J Intern Med Date: 2015-10-30 Impact factor: 2.884